Esperion Therapeutics Inc (ESPR.OQ) Quote| Reuters.com
Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

9.66USD
29 Jun 2016
Change (% chg)

-- (--)
Prev Close
$9.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
132,175
52-wk High
$100.79
52-wk Low
$12.61

ESPR.OQ

Chart for ESPR.OQ

About

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company's segment is the business of researching, developing and commercializing therapies... (more)

Overall

Beta: --
Market Cap(Mil.): $217.75
Shares Outstanding(Mil.): 22.54
Dividend: --
Yield (%): --

Financials

  ESPR.OQ Industry Sector
P/E (TTM): -- 39.54 34.69
EPS (TTM): -2.35 -- --
ROI: -17.68 -6.70 14.13
ROE: -17.87 -6.13 15.35

BRIEF-Esperion Therapeutics provides regulatory update for Bempedoic Acid

* Esperion Therapeutics Inc says intends to initiate planned CVOT in statin intolerant patients who are at high risk for CV disease in Q4 of 2016

Jun 28 2016

BRIEF-Esperion Therapeutics qtrly loss per share $0.65

* Esperion therapeutics provides bempedoic acid development program updates; reports first quarter 2016 financial results

May 04 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.